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Three‑dimensional structure 
of human cyclooxygenase (hCOX)‑1
Morena Miciaccia1,5, Benny Danilo Belviso2,5, Mariaclara Iaselli1, Gino Cingolani3, 
Savina Ferorelli1, Marianna Cappellari4, Paola Loguercio Polosa4, Maria Grazia Perrone1, 
Rocco Caliandro2* & Antonio Scilimati1*
The beneficial effects of Cyclooxygenases (COX) inhibitors on human health have been known for 
thousands of years. Nevertheless, COXs, particularly COX‑1, have been linked to a plethora of human 
diseases such as cancer, heart failure, neurological and neurodegenerative diseases only recently. 
COXs catalyze the first step in the biosynthesis of prostaglandins (PGs) and are among the most 
important mediators of inflammation. All published structural work on COX‑1 deals with the ovine 
isoenzyme, which is easier to produce in milligram‑quantities than the human enzyme and crystallizes 
readily. Here, we report the long‑sought structure of the human cyclooxygenase‑1 (hCOX‑1) that 
we refined to an R/Rfree of 20.82/26.37, at 3.36 Å resolution. hCOX‑1 structure provides a detailed 
picture of the enzyme active site and the residues crucial for inhibitor/substrate binding and catalytic 
activity. We compared hCOX‑1 crystal structure with the ovine COX‑1 and human COX‑2 structures 
by using metrics based on Cartesian coordinates, backbone dihedral angles, and solvent accessibility 
coupled with multivariate methods. Differences and similarities among structures are discussed, 
with emphasis on the motifs responsible for the diversification of the various enzymes (primary 
structure, stability, catalytic activity, and specificity). The structure of hCOX‑1 represents an essential 
step towards the development of new and more selective COX‑1 inhibitors of enhanced therapeutic 
potential.
Prostaglandin endoperoxide H synthases (PGHSs), also known as cyclooxygenases (COXs), catalyze the con-
version of free arachidonic acid (AA), released from cell membrane upon mitogen or mechanical stimuli, into 
Prostaglandin  H2  (PGH2), that represents the committed step in the biosynthesis of prostaglandins, prostacyclin, 
and  thromboxane1. The known COX isoforms (COX-1 and COX-2) are the product of two different  genes2,3. The 
gene that encodes for COX-1 is considered a “housekeeping gene” due to its low levels of expression in most cell 
types. However, high levels of constitutive COX-1 expression have been detected in the gastric mucosa and plate-
lets. In contrast to COX-1, COX-2 expression is typically inducible in response to pro-inflammatory events and 
growth  factors2. COX-1 and COX-2 are of particular interest because they are the major target of non-steroidal 
anti-inflammatory drugs (NSAIDs)3, which bind to the COX active site preventing that AA reaches the catalytic 
 pocket1 and, hence, prostaglandins biosynthesis. Prostaglandins, in particular  PGE2, are crucial mediators impli-
cated in inflammation, angiogenesis and support the growth of several solid  tumors4,5. Therefore, inhibition of 
COXs is relevant to reduce inflammation, pain, and fever, as well as cancer progression.
Compared to COX-2, COX-1 involvement in tumorigenesis has been less  studied5. Recent work demonstrates 
a direct involvement of COX-1 in breast,  ovarian6, head and neck cancer, renal cell carcinoma, and hematologi-
cal  tumors5,7,8. For all these cancers, overexpression of COX-1 could be exploited as a diagnostic  biomarker9–12.
X-ray crystallographic analysis has proven a powerful tool to investigate COX active site and in unraveling the 
binding mode of COX inhibitors. The ovine isoform of COX-1 (oCOX-1) has been crystallographically studied 
over a dozen times in complex with inhibitors and  substrates13. More difficult has been working with the human 
isoform (hCOX-1). Herein, we describe the expression and purification of hCOX-1 from baculovirus-infected 
insect cells that yielded milligram-quantities of the enzyme. Ectopically expressed hCOX-1 yielded crystals suit-
able for structure determination by using X-ray crystallographic analysis.
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Results
hCOX‑1 expression and purification. The production of milligram quantities of correctly folded and 
active hCOX-1 is vital for the structural, biochemical and pharmacological analysis of human COX-1, a key 
target of a plethora of pharmaceuticals, clinically used to treat several human diseases. In this study, we used the 
BacPAK™ Baculovirus Expression System to express large quantities of folded and post-translationally modi-
fied hCOX-1 suitable for structural analysis.
hCOX-1 is 599 amino acids long and includes at the N-terminus a 24-amino acid signal peptide that targets 
the protein to the endoplasmic reticulum for post-translational modification. We aimed to construct a recom-
binant hCOX-1 baculovirus that expresses the protein suitable for nickel affinity chromatography purification 
by using the BacPAK Baculovirus Expression System. The hCOX-1 DNA was PCR amplified from a previously 
generated pFastBac-hCOX-1 plasmid that also contains an 8xHistidine tag (8XHis-tag) placed just after the 
signal peptide, followed by a 7-amino acid TEV protease cleavage site. The amplification was carried out using 
the proofreading Phusion HF DNA polymerase and specific primers containing at their 5′ ends BglII and NotI 
restriction sites. The amplified DNA was evaluated by agarose gel electrophoresis, showing, as expected, a sin-
gle product of about 1800 bp (Supplementary Fig. 1). The purified products were digested by BglII and NotI 
restriction enzymes and ligated with the shuttle plasmid pBacPAK9. Then, the ligation products were amplified 
in bacteria and, once extracted, they were restriction digested to assess the presence of the target gene; the cor-
rect sequence of the insert was verified by sequencing of both strands. The cloning efficiency was about 100% 
(Supplementary Fig. 2). To generate the recombinant expression virus, the transfer vector pBacPAK9 containing 
8XHis-tag hCOX-1 cDNA was transfected into Spodoptera frugiperda cells along with Bsu36 I-digested BacPAK6 
Viral DNA; an in vivo homologous recombination between the plasmid DNA and viral DNA occurred, produc-
ing recombinant  baculovirus14.
To isolate a pure clone of a recombinant virus, the supernatants from co-transfection containing progeny 
viruses were collected and subjected to plaque assay to produce individual plaques (plaque-pick). All plaque-
picks were first amplified to produce Virus Stock I (VSI), then viral DNA was extracted and analyzed by PCR, 
confirming that all clones were  positive15 (Supplementary Fig. 3).
Hereafter, VSI was amplified twice, according to the manufacturer’s instructions, to maximize the yield of 
recombinant protein production. A scale-up production and purification protocol for the hCOX-1 isoenzyme 
was substantially the same as previously described for oCOX-116.
SDS-PAGE analysis of metal affinity chromatography fractions revealed hCOX-1 eluted around 0.25 M imida-
zole; the eluted protein was highly pure as no low molecular weight species were detectable after Blue Coomassie 
staining of the gel (Supplementary Fig. 4).
hCOX-1 protein fractions were pooled and further purified by performing in-solution cleavage, with direct 
addition of  TEV6His protease to the eluted fraction. Following cleavage, the protein solution was loaded on nickel 
beads, where his-tag and  TEV6His were recaptured on the resin. Untagged hCOX-1 was collected in the flow-
through, buffer exchanged and concentrated to 10.4 mg ml−1.
Stability, catalytic activity, and specificity of oCOX‑1 and hCOX‑1. The availability of both ovine 
and human COX-1 let us to verify if their stability, catalytic activity, and specificity are similar or different. In 
particular, their thermal and chemical stability was determined at + 4, − 20, and − 80 °C. Within three months, 
both enzymes stored at the first two temperatures exhibited an impaired catalytic activity, that in turn remains 
unchanged at − 80 °C for the same period of time. Their specific activity, instead, was determined in the pres-
ence of arachidonic acid and one of the different well-known NSAIDs-COX-1 inhibitors (Table 1), such as mof-
ezolac (a diarylisoxazole sold in Japan as Disopain® to treat rheumatoid arthritis and that could be worldwide 
repurposed for neurodegenerative diseases with a marked neuroinflammatory component)17,18; the ibuprofen, 
one of the arylpropanoic acids (profen-series) representative of the most commonly prescribed NSAIDs, and 
indomethacin belonging to the chemical class of indole-acetic acids actually used for treating mild to moderate 
acute pain in adult. The specific activities found were a little higher for hCOX-1 than oCOX-1, even if the two 
values are very similar in all three cases. The similarity could be ascribed to the high sequence identity (92%) 
among the two proteins (Fig. 1).  
Mofezolac inhibited oCOX-1 to a greater extent than the corresponding human enzyme (oCOX-1 
 IC50 = 9.2 µM; hCOX-1  IC50 = 23 µM), ibuprofen oCOX-1  IC50 and hCOX-1  IC50 are comparable being 31 and 
44 µM, respectively. The indomethacin inhibitory potency towards hCOX-1 was found to be of two orders of 
magnitude higher than the ovine enzyme (oCOX-1  IC50 a = 158 µM and hCOX-1  IC50 = 2.9 µM) and with an 
enzyme preference index (EPI) for hCOX-1 equal to 54 (Table 1).
hCOX‑1 crystallization experiments. hCOX-1 crystallization experiments were carried out by following 
the crystallization procedure reported for oCOX-119. The best diffracting crystals (Supplementary Fig. 5) were 
obtained in the presence of 0.5–0.6 M lithium chloride, 10-11 mg/ml of protein concentration, 0.7 M sodium 
citrate, and 1:1 molar ratio between protein and heme  (Fe3+–protoporphyrin IX).
hCOX‑1 crystal structure. hCOX-1 crystals were subjected to X-ray diffraction experiments. Data col-
lection and refinement statistics are shown in Table 2. The data resolution cutoff of 3.36 Å allowed meeting 
requirements of < I/σ(I) >  > 1.5 and  CC1/2 > 50% for the high-resolution shell. The data resolution limit and the 
high value of  Rsym in the high-resolution shell could not be improved by varying crystallization conditions and 
trying different crystals. The hCOX-1 crystal shows P  6522 symmetry, and its asymmetric unit contains a single 
protein molecule (Fig. 2a). According to the PISA  server20, the protein in the asymmetric unit interacts with a 
symmetry-related molecule (symmetry operation y, x, − z-1/3) to form a dimeric biological unit (Fig. 2b), whose 
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Table 1.  oCOX-1  IC50 and hCOX-1  IC50, and the specific activity of the two enzymes. a Determined by 
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Figure 1.  Alignment of human and ovine COX-1. Amino acid sequences of COX-1 from human, h, 
(NM_000962.4) and ovine, o, (NM_001009476.1) were aligned with the ClustalW program. The alignment was 
performed at NPS@ Web server of the PBIL using GONNET weight matrix and formatted with ESPript 3.021. 
The red boxes include identical amino acids in both sequences. Unconserved residues are included in the white 
boxes. Among these amino acids, the proline residues present only in oCOX-1 are shown in the green boxes, 
while the glycine residues present only in hCOX-1 are displayed in the yellow boxes.
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Table 2.  Data collection and refinement statistics of the hCOX-1 crystal structure (PDB code 6Y3C). Outer 
shell statistics are in parenthesis. For the sake of completeness, statistics before and after anisotropy correction 
by the STARANISO server are shown.
Data collection
Wavelength (Å) 0.9795
Space group P  6522
Cell constants a, c (Å) 182.11 103.24
Before STARANISO After STARANISO
Resolution range (Å) 91.05–3.36 (3.45–3.36) 91.05–3.36 (3.48–3.36)
Completeness (%) 99.9 (99.9) 81.1 (25.16)
Redundancy 39.1 (42.2) 39.1 (42.2)
Total number of reflections 582,091 (45,649) 581,081 (61,045)
Unique reflections 14,886 (1081) 14,838 (363)
R sym (%) 0.467 (4.244) 0.493 (3.356)
R meas (%) 0.473 (4.295) 0.499 (3.578)
 < I/σ(I) > 14.3 (1.4) 14.3 (1.5)
CC1/2 (%) 99.9 (63.6) 99.9 (69.0)
Wilson B-factor (Å2) 94.32 94.47
Refinement
R/Rfree (%) 20.82/26.37 (29.17 /36.30)
MolProbity score 1.59
Clashscore 7
Average B-factor (Å2) (protein atoms) 100.54
Average B-factor (Å2) (water atoms) 61.12




RMSD bonds length (Å) 0.002
RMSD bond angles (°) 0.53
Ramachandran favored (%) 96.76
Ramachandran allowed (%) 3.24
Ramachandran outlier (%) 0.00
Figure 2.  hCOX-1 crystal structure (PDB code 6Y3C). (a) Asymmetric unit of hCOX-1: protein is shown 
in blue cartoon, and glycosylation along with glycosylation-linked asparagine residues are in pink stick 
representation. The solvent excluded surface (determined at solvent radius 1.4 Å) of heme and substrate site is 
shown in green. (b) Biological unit of hCOX-1: the two protein molecules forming a functional dimer are shown 
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interaction interface is about 26% of the solvent-exposed area of the monomer. The high free energy calculated 
for dimer dissociation (17.6 kcal/M) suggests that such a biological unit is thermodynamically stable. Diffraction 
data quality is enough to model the expected N-acetyl glucosamine (NAG) chain on N68, N410, N144 that are 
shown in stick representation in Fig. 2a. The validation procedure of the Protein Data Bank server shows quite 
a constant electron density coverage along the entire protein chain. Poorly covered residues having RSRZ > 2, 
where RSRZ is the difference between the experimental electron density and that obtained by the model, nor-
malized by residue type and resolution, are only 4% of the all protein residues and are located at the N-terminus 
and in the regions that span 130–150 and 200–213. Such a density coverage points out the good agreement 
between data and the modeled protein chain. The final model has good geometry relatively to the resolution, 
with 18% of residues having one geometry outliers, and only 1% showing two outliers.
Secondary structure elements and their mutual orientation are shown in Fig. 3a. hCOX-1 protein fold reveals 
the peculiar arrangement of an epidermal growth factor (EGF) and a membrane-binding domain placed on 
the surface of a catalytic domain, quite far from the heme site Fig. 3b. With respect to the EGF domain, the 
membrane-binding domain has more interactions with the catalytic domain and, particularly, with the region 
forming the substrate pocket of the protein. Such protein folding follows that of the oCOX-1, the protein having 
the highest sequence identity with hCOX-1, and that of the hCOX-2.
The heme molecule, which is important for COX activity, was added at 1:1 molar ratio with hCOX-1 monomer 
before crystallization. Such a stoichiometric quantity of heme promoted crystallization resulted in poor electron 
density in the region where heme molecule is expected. Refining the structure with the heme molecule resulted 
in an increase of R/Rfree from 20.82/26.37 to 21.50/26.58. In Fig. 4, the polder map calculated by omitting the 
Figure 3.  hCOX-1 folding. (a) hCOX-1 topology diagram: secondary structure elements are shown in red, 
green, and blue for EGF, membrane-binding domain, and catalytic domain, respectively. β-strands and α-helixes 
are shown as arrows and cylinders, respectively; (b) hCOX-1 domains are shown in cartoon representation in 
the same color code of (a). Solvent excluded surface of the catalytic domain is in yellow color.
Figure 4.  Polder map of heme molecule. Protein residues are shown in gray lines and heme molecules are as 
gray sticks. (a–c) show the polder map contoured at 2.5σ above background for hCOX-1 (PDB code 6Y3C), 
oCOX-1 (PDB code 1U67), and oCOX-1 (PDB code 5U6X).
6
Vol:.(1234567890)
Scientific Reports |         (2021) 11:4312  | https://doi.org/10.1038/s41598-021-83438-z
www.nature.com/scientificreports/
heme group in our structure is compared with those calculated in the same way for two previously determined 
oCOX-1 structures [1U67 (P  6522 symmetry) and 5U6X (P  65 symmetry)]. The density for heme is much weaker 
in the hCOX-1 than the other two structures, confirming the poor occupancy of this prosthetic group in our 
structure. Interestingly, the polder electron density covers only partially the heme molecule, mainly, the portion 
that interacts with protein residues. Such a feature is compatible with a flexible molecule rather than a stable 
molecule at low crystallographic occupancy. To make sure that such electron density features related to the heme 
molecule are not an artifact due to an incorrect choice of space group, data were reprocessed in the alternative 
space group P  65, suggested by the indexing process, where the two protein chains can have different conforma-
tions, but no difference was observed. Unable to confirm the presence of the heme in our crystal structure, we 
decided not to include such a prosthetic group in the final model.
Another region of the enzyme that deserves attention is the substrate site. Even though our hCOX-1 crystals 
were obtained in the absence of molecules that bind the substrate site, a peak of difference (Fo-Fc) electron den-
sity can be observed in this region (Fig. 5a). Fo-Fc density map was compared with that obtained by removing 
arachidonic acid (COXs endogenous substrate) and P6 (highly selective COX-1 inhibitor)22–24 ligand from 1U67 
(Fig. 5b)13 and 5Y6X (Fig. 5c)13, respectively. Although less defined, the peak in our structure shows similar shape 
and orientation to those in the other two structures. All attempts to fit and refine arachidonic acid, or molecules 
present in the crystallization cocktail, were unsuccessful. This prompted us not to model this electron density 
peak in the final structural model.
Comparative analysis of hCOX‑1, oCOX‑1 and hCOX‑2 crystal structures. There are twenty-nine 
crystal structures of oCOX-1 deposited in the Protein Data Bank (thirteen of which crystallized in the space 
group I 222, nine in the space group P  65, and seven in P  6522) and seven crystal structures for hCOX-2 (all 
crystallized in the space group I 222). Differences in protein conformation among these crystal structures could 
be due to different crystallization conditions, crystal packing, or protein sequence. While the first two are prop-
erties of the crystal state, the latter one is related to the intrinsic conformation of the protein. In the case of COX 
proteins, deciphering the intrinsic conformation of the human enzyme is particularly important for drug design 
and development. COX-1 is a functional dimer, and dimerization is strictly required for structural integrity and 
 activity25. Nonetheless, it remains unclear if the COX-1 dimer is built by conformationally equivalent or quasi-
equivalent protomers of COX. With this rationale in mind, we performed a comparative analysis of our hCOX-1 
with the crystal structures of oCOX-1 and hCOX-2 deposited in the PDB using different metrics and considering 
the chains of the biological unit of each structure separately.
As a first step, we compared the experimental coordinate errors of the structural models, as estimated by 
the diffraction-data precision indicator (DPI) (Supplementary Fig. 6). Our hCOX-1 crystal structure holds a 
coordinate error of 0.59 Å, mainly due to the medium data resolution (3.36 Å). Comparable errors are shown by 
oCOX-1 crystal structures with P  6522 (average error of 0.41 Å) and I 222 symmetry (average error of 0.46 Å). 
In this latter case, the spread of DPI values is very large, ranging from 0.10 Å for 2AYL and 1Q4G to 1.24 Å 
for 1PGF and 1PGG. Crystal structures of hCOX-2 and oCOX-1 with P  65 symmetry are systematically more 
precise, having, in both cases, an average error of 0.28 Å. The systematic trend of experimental errors among 
COXs reflects the quality of diffraction data, and suggests the following trend: first, hCOX-1 is the most chal-
lenging isoform to crystallize; second, COX-2 is intrinsically more stable than COX-1 and hence more likely to 
crystallize; third, among oCOX-1 structures deposited in the database, there is an empirical correlation between 
model accuracy and crystal symmetry with the COX-1 structure solved in space P  65 being the most accurate, 
followed by P  6522 and finally I 222.
Figure 5.  Fourier difference (Fo-Fc) electron density map contoured at >|3σ| (positive and negative peaks are in 
green and red mesh, respectively) in the substrate site for (a), 6Y3C (hCOX-1), (b) 1U67 (oCOX-1:AA complex 
crystal), and (c) 5U6X (oCOX-1:P6 complex crystal). Enzymatic protein residues are in gray lines and AA or 
P6 in the substrate site in gray sticks. Fourier difference electron density map was obtained by removing ligand 
molecules from the structures.
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Comparison based on Cartesian coordinates. We superimposed each independent chain of hCOX-1, 
oCOX-1, and hCOX-2 with each other to generate a matrix (65 chains × 65 chains) of overall Cα RMSD, which 
was subjected to hierarchic clustering. Despite the large heterogeneity of diffraction data quality of COXs crys-
tals (Supplementary Fig. 6), the crystal structures that are homogeneous by protein, source, and crystallographic 
symmetry were grouped consistently in the resulting matrix (Fig. 6), as they have similar RMSD values. It can 
be noted that the two chains of the same crystal structure are grouped in most of the cases, indicating that the 
functional dimer is preferentially made of two conformationally-equivalent units. Moreover, Fig. 6 clearly shows 
the cluster of hCOX-2 chains, which are very different from the oCOX-1 chains, and the clusters of oCOX-1 
chains with P  6522 and I 222 symmetry, pointing out the high structural similarity (inter-cluster RMSD < 0.4 Å) 
of these three sets of structures.
oCOX-1 structures with P  65 symmetry are spread into three clusters, indicating the higher structural het-
erogeneity related to this crystal packing, where two symmetry-independent chains form the biological unit. A 
further cluster has slightly higher inter-cluster RMSD values (between 0.4 and 0.6 Å) and includes the following 
outliers: our hCOX-1 crystal structure, 2OYU, a oCOX-1 structure with P  6522 symmetry, the chain A of the 
structure 3N8X and the structure 3KK6, both oCOX-1 crystallized in P  65. The papers related to these two lat-
ter outliers show that data merging by using P  65 and P  6522 provides comparable  Rsym  values26,27, a feature that 
could explain why these structures group with oCOX-1 structures crystallized in P  6522 rather than with those 
crystallized in P  65. Interestingly, the sum of all RMSD values obtained in the case of the human isoform is the 
highest compared to those obtained for the other COX-1 structures (Supplementary Fig. 7). In the case of pair-
wise comparison between oCOX-1 structures and our hCOX-1, the average of the RMSD values is ~ 0.5 Å, and 
it is ~ 0.8 Å in the case of comparison with hCOX-2 crystal structures, despite the low sequence identity (60%).
An in-depth view of the above structural deviations is provided in Fig. 7, where the hCOX-1 crystal structure 
is used as a reference for pairwise superposition, and the residue-by-residue averaged RMSD values for each 
group of structures are plotted against the residue number. It can be noted that the RMSD values of A (red) and 
B (black) chains do not show significant differences within the same group. A second observation regards specific 
regions of the protein affected by high RMSD values. By focusing on the left column (superposition between 
hCOX-1 and oCOX-1 structures), it is possible to observe that the region between 270 and 290 in the catalytic 
domain is systematically affected by high RMSD values regardless the crystal symmetry. We verified that this 
very flexible region is mainly responsible for the clustering shown in Fig. 6, as it holds the same conformation 
in crystal structures within the same cluster, and slightly different conformations for inter-cluster structures 
(Supplementary Fig. 8).
Figure 6.  Matrix of the Cα pairwise RMSD values calculated between individual chains of the 37 structures 
of hCOX-1, oCOX-1, and hCOX-2 present in the PDB. Chains are ordered based on a hierarchical clustering 
algorithm having RMSD as distance metrics. They are labelled on the top by using the PDB code, the type 
(hCOX-1 or hCOX-2), the space group (only for oCOX-1), and the chain letter (A or B are reported only if they 
do not fall in the same cluster).
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Interestingly, such a region is poor of residue variations among hCOX-1 and oCOX-1; thus, conformational 
changes are unlikely related to differences in the protein sequence. Differently from the region 270–290, residues 
between 70 and 110, located in the first two α-helices of the membrane-binding domain, show high RMSD values 
only compared to oCOX-1 protein crystallized in the space group I 222. We verified that the same feature arises 
when comparing oCOX-1 crystal structures with P  6522 (the same symmetry of our hCOX-1 crystal structure) 
or P  65 symmetry with those with I 222 symmetry (Supplementary Fig. 8). Thus, this conformational variation 
was ascribed to the different effect that crystal packing exerts on the protein conformation in an orthorhombic 
versus hexagonal lattice. It is worth noting that the same effect does not exist if our hCOX-1, or oCOX-1 with P 
 6522 symmetry if compared with oCOX-1 crystallized in the P  65 space group. Such a result can be explained by 
considering that these structures have similar unit cells and crystal packing and differ only in the extension of 
the asymmetric unit. In addition to crystal packing, also differences in ligand interactions could contribute to 
the high value of RMSD found in the region 70–110. Indeed, ligands found for oCOX-1 in I 222 are localized in 
different way with respect to the citrate ions found in our structure (Supplementary Fig. 9, Supplementary Dis-
cussion 1). Similar differences can be observed also by comparing our structure with hCOX-2. It is worth noting 
that, since differences in crystal packing and ligand interaction are not directly related to the protein sequence, 
the high values of RMSD observed in the region 70–110 are unlikely related to intrinsic protein conformation, 
thus they should not affect inhibitor binding.
When comparing hCOX-1 and hCOX-2 (Fig. 7d), it can be noted that in addition to the regions 270–290 
and 70–110, highlighted in the comparison between hCOX-1 and oCOX-1, also regions 125–175 (N-terminus 
of the catalytic domain), 400–420 and 470–520 both included in the catalytic domain show large deviations.
Figure 7.  Average residue-by-residue RMSD values calculated after superposition of hCOX-1 (6Y3C) with 
(a) oCOX-1 crystallized in the I 222 space group (PDB codes 1Q4G, 2AYL, 1PTH, 1PRH, 1PGG, 1PGE, 1PGF, 
1HT8, 1EQH, 1HT5, 1CQE, 1EBV, 1EQG), (b) oCOX-1 crystallized in the P  65 space group (PDB codes 
3KK6, 3N8Z, 3N8X, 5WBE, 3N8V, 4O1Z, 3N8Y, 3N8W, 5U6X), (c) oCOX-1 crystallized in the P  6522 space 
group (PDB codes 1U67, 2OYE, 2OYU, 1IGZ, 1DIY, 1FE2, 1IGX), and (d) hCOX-2 crystallized in the I 222 
space group (PDB codes 5F19, 5IKQ, 5IKT, 5KIR, 5F1A, 5IKR, 5IKV, 5KIR) to the hCOX-1 (6Y3C) crystal 
structure. Standard deviation for each residue is shown in gray color. RMSD values related to chain A and chain 
B (nomenclature refers to that adopted for 5U6X shown at bottom right in the figure) are shown in red and 
black, respectively. Here, regions 70–110 and 270–290 are shown in yellow and magenta color. In the case of 
oCOX-1 crystallized in P  6522, the biological unit contains a homo-conformational dimer, therefore only chain 
A is shown. The numbering of residues refers to hCOX-1 structure. On the top of the figure, variations between 
hCOX-1 and oCOX-1 (left) and hCOX-2 (right) are shown, along with hCOX-1 domains.
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Comparison based on backbone dihedral angles. In addition to the analysis based on Cartesian 
coordinates, we performed a comparative analysis based on backbone dihedral angles more focused on differ-
ences due to hinge motion. Profiles describing the residue-by-residue hinge flexibility have been calculated in 
terms of the Protein Angular Value (PAV). The 74 × 550 (chains × residues) matrix formed by the PAV profiles 
was processed by principal component analysis (PCA) to reduce the dimensionality of the problem and assess 
the separation among structural models in the 2D space defined by the first two principal components. Data 
points, representing structural models, can be grouped according to their position in the PC2 vs PC1 scores 
plot (Fig. 8a). We found that the chains belonging to the same structure have very close PC1/PC2 coordinates 
Figure 8.  Comparison of hCOX-1, oCOX-1, and hCOX-2 structural models by principal component analysis 
applied on PAV (a–d) and SASA (e,f) profiles. A restricted number of COX-1 structural models is considered 
in (c,d). [On the left is shown the score plot of the first two principal components, where representative points 
are grouped according to a hierarchic clustering algorithm. 85% confidence level ellipses are shown, and PDB 
codes associated with representative points are reported. The percentage of the total data variance explained 
by each principal component is shown on the axes. On the right are shown the loadings of the first (black) and 
second (red) principal components, the structural model 6Y3C colored according to the loading values, from 
red for higher positive to blue for higher negative (b,f), and the superposed structural models with 6Y3C and 
3KK6 colored respectively in green and blue (d). Arrows point to protein residues having the highest and lowest 
loadings values. Residues falling in these regions are drawn in “bonds” representation in (f)].
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in the score plot to such an extent that the two chains cannot be distinguished. This result points out that each 
analyzed structure is made by two chains having the same hinge points, thus enforcing the hypothesis that their 
biological unit contains a homo-conformational dimer. Moreover, Fig. 8a shows that hCOX-2 structures are 
consistently separated from COX-1 structures and are grouped in a very narrow cluster, confirming their higher 
structural homogeneity already observed by RMSD analysis. Instead, COX-1 structures exhibit a larger spread, 
with a huge separation of oCOX-1 structures with P  6522 symmetry, located at high positive PC1 values, and 
of oCOX-1 structures with I 222 symmetry, located at high negative PC2 values. A cluster, including oCOX-1 
structures having symmetry P  65, our hCOX-1 structure and the outlier structures 2OYU, 1PRH, 2AYL, and 
1Q4G is located at PC1 and PC2 values. Residues that are responsible for the above separation, as summarized 
in Table 3, can be identified among the highest values (positive or negative) of the PCA loadings (Fig. 8b). The 
effect of each individual range of hinge residues on structural separation has been determined by applying PCA 
on the PAV matrix restricted to that range. With this method, we were able to identify the residues 269–270 and 
574–575 as main responsible for the separation of hCOX-2 crystal structures, the residues 95–96 and 400–402 
as responsible for the separation of oCOX-1 P  6522 structures and the region 274–287, which is able to separate 
oCOX-1 structures with P  6522 and I 222 symmetry. This latter region is interested in inter-molecular hydrogen 
bond interactions with the glycosylation site Asn410 in oCOX-1 crystal structures (see Supplementary Table 1).
A comparative structural analysis more focused on the cluster containing our hCOX-1 structure has been 
carried out by removing from the selection the structures having higher deviations, i.e., hCOX-2 and oCOX-1 
with P  6522 and I 222 symmetry (Fig. 8c). By using this strategy, the hCOX-1 (6Y3C) structure is separated 
from remaining oCOX-1 crystal structures by PC2, while PC1 discriminates the 3KK6 chains, confirming that 
this latter structure is peculiar respect to the other oCOX-1 with P  65 symmetry, as found by RMSD analysis, 
and 5U6X, which was indeed used to drive the phasing of 6Y3C by molecular replacement. Loading analysis 
(Fig. 8d) allows identifying residues mainly responsible for the discrimination among selected structures: 438 
and 275, which separates 3KK6 along PC1, and 322, 218 and 126, which separate 6Y3C along PC2. It should 
be noted that the conformational changes shown by the above residues in the discriminated crystal structures 
could reflect uncertainties due to limited data resolution. Thus, at this level of details, the discrimination is 
not significant, as confirmed by the limited data variability explained by the first two principal components 
(35%) in Fig. 8c. PCA applied to PAV appears able to distinguish crystal structures according to conformation 
changes, even if small, and, therefore, it represents a valuable diagnostic tool to check crystal structures against 
an ensemble of homologous crystal structures. For hCOX-1, we verified that aligning the orientation of residues 
around Thr322, Pro218 and Ser126 to that shown by the  P65 oCOX-1 chains does not lead to a better structural 
refinement against diffraction data.
Due to the nature of the crystal structure used as input for PAV analysis, such results rely on static informa-
tion only. In an attempt to analyze flexibility from more dynamic information, we performed a coarse-grained 
modelling on our hCOX-1 (6Y3C) and on the oCOX-1 crystal structure having the highest resolution among 
those ones with the same space group of 6Y3C (2OYU) (Supplementary Discussion 2). The residue-by-residue 
Root Mean Squared Fluctuations (RMSF) values obtained by this modelling appear slightly higher in the case 
of hCOX-1 (Supplementary Fig. 10a). By plotting RMSF values against Solvent Accessible Surface Area (SASA) 
values (Supplementary Fig. 10b), it is possible to observe that residues showing largest changes of flexibility 
between the two isoforms also show very large changes of SASA due to crystal contacts, but no differences for 
SASA due to dimer formation. This result suggests that residues characterized by largest differences in flexibility 
between the two isoforms are involved in crystal contacts, but do not interfere with dimer formation. In addition, 
it would provide a rationale to the fact that the two proteins have similar activity (related to dimer formation) 
and different crystallizability (related to crystal packing).
Comparison based on COXs solvent accessibility. Conformational differences in protein structures 
usually result in significant differences in protein properties, also in the case of proteins with high homology or 
similar functions. Among these properties, solvent accessibility is of paramount importance because it deter-
mines the possibility of exogenous molecules to target protein pockets. RMSD and flexibility analysis suggested 
that our hCOX-1 structure is comparable to oCOX-1 structures and well separated with respect to hCOX-2 
structures. To assess how solvent accessibility discriminates COXs, we calculated the residue-by-residue SASA 
Table 3.  Key residues determined by backbone dihedral angles comparative analysis applied on hCOX-1, 
oCOX-1, and hCOX-2 crystal structures. In the table are reported: the residue number, the structural elements 
and the structural region where the residues are located, the principal components having high loadings values 
in the specific residue range (fourth column) and the crystal structures mainly separated by applying PCA to 
the specific residue range (last column).
Residue number Structural element Structural region
Principal components 
interested
Crystal structures mainly 
separated
95, 96 α3-α4 Substrate site PC1, PC2 oCOX-1  P6522
269, 270 α6-α7 loop Close to heme site PC2 hCOX-2
274, 281, 287 α6-α7 loop
Close to Asn410 Glycosyla-
tion site PC1 oCOX-1  P6522, oCOX-1 I222
400, 401, 402 β12 NAG site PC1 oCOX-1  P6522
574, 575 C-term loop C-term PC2 hCOX-2
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by scanning the protein surface with a probe of 1.4 Å of radius (water radius), and we performed PCA on SASA 
profiles, The resulting score plot (Fig. 8e) shows a clear separation between hCOX-2 and hCOX-1 structures 
along PC1, which explains 58.5% of the total data variance. According to the loading plots (Fig. 8f), the resi-
due 98, which is a highly exposed tryptophan in COX-1 structures (SASA ≈ 200 Å2) and a glycine in COX-2 
structures (SASA ≈ 50 Å2), is mainly responsible for this separation. Instead, COX-1 structures are separated 
along PC2, which explains only a small percentage of the total data variance (7.8%). oCOX-1 crystal structures 
are grouped according to their crystal symmetry, with I 222 and P  6522 structures located respectively at large 
negative and positive values of PC2 scores, and P  65 structures positioned at small values of PC2 scores. As in 
the case of PAV analysis, our hCOX-1 crystal structure is located in a peripheral region of the I 222 cluster of 
oCOX-1 structures, pointing out slightly different solvent accessibility of this structure with respect to most of 
the other oCOX-1 structures with same packing. Loadings analysis (Fig. 8f) clarifies that the solvent accessibil-
ity separation among COX-1 structures is due to the leading contribution of few differently exposed residues: 
Lys169 and Glu268, having the highest negative PC2 loadings values, hence responsible for the separation of 
the I 222 crystal structures, and Asp249, Pro160, and Phe356 , having the largest positive PC2 loadings values, 
hence responsible for the separation of the P  6522 crystal structures. These residues are not mutated and do not 
assume particular conformations in hCOX-1, so that it is not discriminated along PC2 (the 6y3c PC2 score value 
is nearly zero in Fig. 8e).
Highly exposed residues dominate structural comparison based on solvent accessibility, and in fact, all the 
above residues are found on the protein surface. However, it is interesting to perform a solvent accessibility 
analysis dedicated to two pockets that are important for COX activity, i.e., the substrate and heme sites. To this 
aim, SASA was calculated by increasing the probe radius from 1.4 to 6.0 Å for residues located in these sites and 
for three representative crystal structures: 6Y3C (hCOX-1), 1U67 (oCOX-1), and 5F19 (hCOX-2). Such range 
of probe radius allowed to get information both from small (at low radius) and large (at high radius) solvent 
channels, thus providing a complete view of the accessibility of the two sites. SASA has been calculated after the 
removal of ligand molecules from protein structures. The ligand pocket volume can be characterized by the curves 
describing the SASA values averaged over the pocket residues as a function of the probe radius (Supplementary 
Fig. 12). For averaging, we consider only the contributes from conserved residues among proteins. In this way, 
SASA takes into account the steric hindrance of all residues but is not affected by the difference in the molecular 
surface of the residues exploited for averaging. The result of this analysis shows similar accessibility for hCOX-1 
and oCOX-1. In the case of the substrate site, we found that the solvent accessibility of hCOX-2 is higher than 
COX-1 proteins and decreases faster by increasing the probe radius. For the heme site, the accessibility of the 
three proteins is the same at 1.4 Å probe radius and, once again, it decreases faster for hCOX-2. Therefore, also 
by restricting the analysis to the two pockets that are important for COX activity, we found similarity between 
hCOX-1 and oCOX-1. Interestingly, SASA decreases significantly between 1.4 and 2.5 Å probe radius regardless 
of protein sequence, and such a decrease is more pronounced in the case of hCOX-2.
In the case of the heme site, SASA can be ascribed to a different steric hindrance due to residue variations 
rather than to different conformations. Indeed, the SASA analysis performed on protein molecules converted 
in polyalanine chains, so that the effect of side chains is excluded from calculations (Supplementary Fig. 13), 
provides the same accessibility for each of the three protein molecules. Instead, in the case of the substrate site, 
accessibility appears to be related to different conformations, because the SASA plot obtained for polyalanine-
converted protein molecules has the same features.
A detailed view of the two pockets (Fig. 9) can be used to interpret the above analysis result. In the case of 
the heme site (Fig. 9b), hCOX-1 and oCOX-1 have the same residues, which explains the similar trend of their 
solvent accessibility. The faster drop of SASA curves of hCOX-2 can be explained by the presence of residues that 
are bulkier in the hCOX-2 than COX-1 proteins (particularly for 387, 446, and 214). In the case of the substrate 
Figure 9.  Comparison of the substrate (a) and heme (b) sites of COX proteins. hCOX-1 (6Y3C) is in cyan 
color, oCOX-1 (1U67) in green color, and hCOX-2 (5F19) in black color. Residues not conserved among the 
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site (Fig. 9a), hCOX-1 and oCOX-1 have different residues, but these variations do not affect their SASA trends, 
which are still similar.
Comparison of glycosylation sites. Our crystal structure clearly shows the same glycosylation site of 
oCOX-1 and hCOX-2 (asparagine residues 68, 144, and 410). To compare intra- and inter-molecular hydrogen 
bond interactions occurring in these glycosylation sites, the crystal structures 2OYU, 1Q4G, 4O1Z, and 5F19 
have been considered, as they have the highest data resolution among the oCOX-1 crystallized in the P 6522, 
I222, P 65 space group, and the hCOX-2 crystallized in the I 222 space group, respectively. Inter- and intra-
molecular interactions are shown in Supplementary Tables 1 and 2, respectively. Five intra-molecular hydrogen 
bonds are conserved among the proteins under investigation: Asn144-Ser146, Asn410-Gln406, Asn68-Gln42, 
Asn68-Tyr55, and Asn410-Leu408. The last interaction is conserved in hCOX-2, despite Leu408 is mutated in 
Ile. In addition, hCOX-1 and most of the oCOX-1 crystal structures share the interactions Asn144-Glu140, 
Asn410-Ser412, Asn410-Met413, and Asn68-Pro67. In the case of hCOX-2, Asn410-Ser412 occurs at a distance 
slightly higher than that considered for our comparison (3.2 Å), while the other two interactions are likely lost 
due to the mutations of Met413 and Pro67 in Ile and Glu residues, respectively. Instead, Asn410-Asp416 appears 
conserved in oCOX-1 crystallized in P  65 space group (4O1Z) and in hCOX-2, where Asp416 is mutated in Glu. 
Importantly, we do not found interactions neither present nor absent only in hCOX-1.
On the contrary, inter-molecular hydrogen bonds do not involve glycosylation sites in hCOX-1, differently 
from oCOX-1 and hCOX-2. For these two proteins, we found that the glycosylation on Asn144 plays an important 
role in dimer formation (Supplementary Fig. 11a). Asn144 interacts with Glu239, which is mutated in alanine 
in hCOX-2. Here, the interaction is formed with Leu238 that, interestingly, appears to shift the α-helix 237–245 
much more than the Asn144-Glu239 interaction does in oCOX-1. The glycosylation site on Asn410 is involved 
in inter-molecular hydrogen bonds only in oCOX-1 crystal structures. Particularly, Asn410-Gln282 characterizes 
oCOX-1 crystallized in the I222 space group (1Q4G), and Asn410-Gly278 characterizes those crystallized in the 
P  6522 and P  65 space groups (2OYU and 4O1Z) (Supplementary Fig. 11b-d). It is noteworthy that in the case of 
2OYU and 4O1Z, the position of the amidic carbon atom of the N-acetylglucosamine bound to Asn410 should 
be inverted with that of the oxygen atom of the same group to allow the interaction between this glycosylation 
and Gly278. Finally, glycosylation on Asn68 interacts with Asp584 and Leu176 in the case of oCOX-1 crystallized 
in  P65 (4O1Z) and hCOX-2 (5F19), respectively (Supplementary Fig. 11e-f).
Discussion
For decades, oCOX-1 has been exploited as a surrogate for the human enzyme, which is more challenging 
to produce in milligram-quantity and recalcitrant to  crystallization13. In this paper, we report the first three-
dimensional crystal structure of hCOX-1 along with an extensive structural comparison with known crystal 
structures of the constitutive (COX-1) and inducible (COX-2) isoforms of the prostaglandin-endoperoxide H 
synthase. hCOX-1 has a very high sequence identity with oCOX-1 (92%) and, like the ovine enzyme, also crys-
tallizes in a hexagonal space group in the presence of lithium chloride and sodium  citrate19,28. The remaining 
crystallization cocktail exploits PEG 4 K as a precipitant and leads to an orthorhombic unit cell, in which protein 
molecules are more tightly packed than those in the hexagonal cell (the solvent content is ≈ 72% and ≈ 65% for 
orthorhombic and hexagonal unit cell, respectively), likely due to the lower ionic strength of the crystallization 
cocktail. A comprehensive analysis of the diffraction-data precision indicator (DPI) among known COX crystal 
structures (Supplementary Fig. 6) pointed out the lower crystalline order of hCOX-1 with respect to oCOX-1 s 
and hCOX-2 s.
In the comparative analysis of the hCOX-1 crystal structure with those of the ovine enzyme and hCOX-2, 
we considered different types of variables connected to crystal structures: (1) Cartesian coordinates, aiming at 
identifying specific regions showing conformations changes, (2) backbone dihedral angles, aiming at locating 
hinge points responsible for variations in protein flexibility, (3) solvent accessibility, aiming at finding differently 
exposed residues. All the analyses agree in confirming that conformationally equivalent protein units make the 
biological unit of hCOX-1, oCOX-1 and hCOX-2 crystal structures. We delineated two regions characterized by 
positional deviations between hCOX-1 and all the other structures investigated: the α6-α7 loop, comprising resi-
dues from 270 to 290, and the region 70–110, covering the first two α-helices of the membrane-binding domain. 
The first region is a key region for determining separations among crystal structures due to its intrinsic flexibility, 
which is influenced by changes in sequence or symmetry. Here, no significant differences have been observed 
between oCOX-1 and hCOX-2 with respect to our hCOX-1 by observing ligand interactions and interactions 
involving glycosylation sites. The second region is mainly affected by crystal packing variations (orthorhombic 
versus hexagonal). Such region shows differences in ligand interaction between hCOX-1 and oCOX-2 crystallized 
in I 222 and difference in interactions involving the glycosylation sites Asn68 of hCOX-1 and hCOX-2. Other 
regions characterized by large deviations emerged from the comparison of our hCOX-1 structure with hCOX-2 
ones and could be explained by the differences between the interaction involving the glycosylation sites Asn144 
and Asn410 of these two proteins.
The analysis based on backbone dihedral angles confirmed the key role played by the above regions to deter-
mine separations among COX-1 and COX-2 structures, as specific hinge residues have been systematically found 
within them (Supplementary Table 3). In other words, we have determined the residues that, changing their 
orientation, induce large variations of the position of nearby residues, which means that detected differences in 
the relative position of protein regions in different structures can be attributed to hinge motion. For example, 
within the region 270–290 we were able to identify residues 274, 281 and 287 as primarily responsible for the 
separation of oCOX-1 structures with P  6522 symmetry, and residues 269, 170 and 287 as responsible for the 
separation of hCOX-2 structures and oCOX-1 structures with I 222 symmetry (Table 3). Residues 95 and 96 are, 
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instead, hinge points that determine unique conformations of the 70–110 region in P  6522 oCOX-1 structures 
and in 1PRH (Table 3). Additional separation of hCOX-2 structures is also characterized by unique conforma-
tions of their C-term loop, determined by changes in orientations of the hinge residues 574 and 575 (Table 3).
A flexibility analysis performed on similar COX-1 structures highlighted residues showing conformational 
changes, which are responsible for the discrimination of few outlier crystal structures. In particular, peculiar 
conformations of Thr322, Pro218, and Ser126 were found in our hCOX-1 crystal structure when compared 
with those of the  P65 oCOX-1 crystal structures. It is not clear if such differences are originated by variations 
in the primary structure or are an effect of the limited data resolution. In this respect, the combined PAV-PCA 
analysis has shown its potentiality in pinpointing divergences in the orientation of residues within an ensemble 
of homologous crystal structures.
The comparative analysis based on solvent accessibility highlighted the role of residue 98 in discriminating 
hCOX-2 structures due to the huge change in its side chain going from hCOX-2 to hCOX-1/oCOX-1 sequence 
(Gly to Trp). This residue still falls in the region 70–110 emerged from the RMSD and dihedral angle analyses. 
A study dedicated to characterizing the solvent accessibility of the substrate and heme sites has revealed quite a 
similar shape of these cavities in hCOX-1 and oCOX-1 crystal structures.
The two regions whose conformation is peculiar for our hCOX-1 are shown in Fig. 10. The region between 
residue 270–290 (Fig. 10a) is part of the loop surrounding the heme site and does not appear directly involved in 
the electron-transfer mechanism occurring at this site between prostaglandin  G2  (PGG2) and prosthetic group; 
however, by considering its position on the protein surface, a role of this region in the binding mechanism of 
 PGG2 to COX-1 can not be excluded. The region 70–110 (Fig. 10b, red color) links EGF to the membrane-binding 
domain and, therefore, is close to the substrate pocket. Picot et al. divide such a pocket into two regions named 
lobby and active site, both important for inhibitor  binding1,5,28. The lobby site is very close to the region between 
residues 70 and 110; therefore, differences in the conformation of this region are expected to affect the lobby 
region, thus the inhibitor binding mechanism.
In summary, the crystal structure of hCOX-1 described in this paper represents a significant achievement 
in structural biology as well as medicinal chemistry, which paves the way for the development of new highly 
selective  inhibitors29–32. Co-crystallization studies with substrate molecules and small-molecule inhibitors will 
be instrumental in clarifying the unique biochemical properties of the human enzyme. Future studies that build 
upon the structure presented here will help in the development of novel therapeutics and imaging-probe that 
target hCOX-1 for unmet clinical diagnosis of diseases in which hCOX-1 is a  biomarker9,10.
Materials and methods
Cell culture reagents were purchased from EuroClone (Milan, Italy). Protoporphirin IX (Hemin), trizma base, 
potassium chloride, imidazole, sodium citrate tribasic dihydrate and lithium chloride, Amicon Ultra-4 10 kDa 
MWCO centrifugal filter device was purchased from Merck. Nickel-NTA agarose beads (low density), n-octyl 
β-D-glucopyranoside (β-OG) and phenylmethylsulfonyl fluoride (PMSF) were from Gold Biotechnology. Hexa-
ethylene Glycol Monodecyl Ether  (C10E6) detergent was purchased from Anatrace (Maumee, OH). Phusion 
High Fidelity (HF) DNA was from Biolabs. Sf-900 II SFM medium, HALT protease inhibitor single-use cocktail 
EDTA-free, Pierce BCA protein assay kit, Snakeskin dialysis tubing (10 kDa MWCO, 35 mm), and glycerol were 
purchased from Thermo Fisher Scientific Italia (Monza, Italy). TGX 10% precast polyacrylamide gels and all rea-
gents for SDS-PAGE were purchased from BIO-RAD Laboratories Srl (Milan, Italy). Tobacco Etch Virus (TEV) 
protease was produced as  described33. Oxygraph buffer: 200 mM Tris–HCl (pH 8.3), 2 M KCl, 1 mM phenol.
Construction of the baculovirus recombinant expression vector, protein production and puri‑
fication. Cloning into baculovirus DNA of hCOX-1 cDNA bearing an import signal peptide followed by 
an N-terminal 8X-His tag and a TEV cleavage was carried out as follows. Briefly, hCOX-1 cDNA was obtained 
Figure 10.  Regions whose conformation is peculiar for hCOX-1. Protein units forming the dimer are shown in 
white and gray surface. (a) The heme molecule is shown in stick representation and the region 270–290 in green 
color. (b) The region 60–100 is shown in red color.
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by PCR using Phusion High Fidelity (HF) DNA polymerase and two specific primers For and Rev bearing at 
their 5′-end a BglII and a NotI site, respectively. Primer sequences (5′ to 3′) are: PBac.hCOX-1.BglII.For: CAC 
AAG ATC TGA TAT GAG CCG GAG TCT CTT   and  PBac.hCOX-1.NotI.Rev: CAC AGC GGC CGC TCA GAG CTC 
TGT GGATG. DNA template was a recombinant pFastBac1/hCOX-1 cDNA gently provided by Prof. William 
Smith (Michigan University). The PCR reaction was carried out in a 50 µl volume, using 3 ng of DNA, 0.2 mM 
dNTPs, 0.5 μM for each primer, 1X Phusion HF buffer containing  MgCl2 and 1 U of Phusion High-Fidelity 
DNA Polymerase (BioLabs). After heating at 98 °C for 40 s, the reaction was subjected to 30 cycles consisting 
of 98 °C for 30 s, 68 °C for 1 min and 72 °C for 40 s; the final elongation was performed at 72 °C for 7 min. The 
amplification product was purified using Eurogold Cycle Pure kit (Euroclone) according to the manual instruc-
tions, and quantified by measuring the absorbance at 260 nm with the NanoDrop 1000 (Euroclone); it was then 
restriction-digested with BglII and NotI, purified, quantified as before, and finally inserted into the BglII/NotI 
sites of the pBacPAK9 baculovirus shuttle vector (Clontech), using standard DNA manipulation techniques. 
For DNA ligation the Rapid DNA Ligation Kit (Roche) was used according to the manufacturer’s protocol, to 
yield the pBacPAK9/hCOX-1 recombinant vector. Ligation mixture was transformed into XL1-blue competent 
E. coli cells according to the standard protocol employing  CaCl2. Positive clones were identified by restriction 
digestion of the miniprep DNA; the correct sequence of the insert was verified by automatic sequencing of both 
strands (Eurofins Genomics Italy). pBacPAK9/hCOX-1 plasmid and linearized baculovirus DNA (BacPAK6 
Viral DNA Bsu36 I digest) were co-transfected in Spodoptera frugiperda (Sf9) cells according to the manufactur-
er’s  protocol34. The co-transfection supernatant was subjected to plaque assay to obtain individual viral plaques; 
four single and well separated agarose plaques corresponding to pure viruses were picked and immersed into 
500 μl of Sf-900II SFM (Gibco) with 1% penicillin/streptomycin (P/S) (Gibco) and 5% fetal bovine serum (FBS) 
(Gibco) for 16 h at + 4 °C in the dark, to allow viruses to diffuse out of the agarose. Putative recombinant viruses 
from each plaque were tested for the presence of hCOX-1 insert; for that, each plaque supernatant was subjected 
to a one-step amplification, yielding Virus Stock I (VSI), from which the DNA viral was extracted according to 
McCarthy CB et al. with some  modifications15. A 200 μl volume of four VSI was lysed by gentle mixing with an 
equal volume of Lysis Buffer (100 mM Tris–HCl pH 7.6, 10 mM EDTA, 0,25% SDS) followed by a 10-min incu-
bation at room temperature. Samples were extracted once with phenol/chloroform/isoamyl alcohol and once 
with chloroform/isoamyl alcohol; the nucleic acids were ethanol precipitated, dissolved in water and quantified 
spectrophotometrically. A 100 ng amount of viral DNA was analyzed by PCR in a final volume of 50 μl, using 
Taq Polymerase TaKara (Clontech) (2.5 U), dNTPs 0.2 mM, 1 μM of each specific primer For and Rev used for 
cloning (see above). After heating at 98 °C for 15 min, the reaction was subjected to 30 cycles of 98 °C for 30 s, 
52 °C for 1 min and 72 °C for 2 min, followed by an extension at 72 °C for 5 min. All of the four analyzed plaques 
resulted positive. One VSI was chosen, that was amplified twice yielding VSII and VSIII; the latter was titred by 
plaque assay (~ 5 × 108 pfu/ml) and used as inoculum stock for recombinant protein expression.
Sf9 insect cell culture suspension at a cell density of 2 × 106 cells/ml in 4 L of the Sf-900 II SFM medium (5% 
FBS, 1% P/S) was infected with the recombinant virus stock VSIII at a multiplicity of infection (pfu/cell) of 10. 
After 72 h, infected Sf9 cells were harvested by centrifugation at 900xg at + 4 °C for 20 min. The cell pellet was 
rapidly cooled in liquid nitrogen and stored at − 80 °C until use. The following steps were performed at + 4 °C. For 
8xHis-tagged hCOX-1 purification, cell pellet was resuspended in 30 ml of cold lysis buffer [20 mM Tris–HCl pH 
8.0, 100 mM KCl, containing Complete EDTA-free protease inhibitor (Roche) and 1 mM PMSF] and disrupted 
by sonication (7 microtip of potency, 1″ pulse on and 4″ pulse off for 5 min, sonicator Branson) on ice (ovine or 
human COX-1/Sf9 sonicated pellet).  C10E6 detergent was added (1.12% w/v) and solubilization was performed 
with gentle shaking at + 4 °C overnight (o/n). The lysate was clarified by centrifugation at + 4 °C for 75 min at 
62,000×g , and the resulting supernatant was incubated with  Ni2+-NTA agarose beads (low density, 50% slurry) 
pre-equilibrated twice with 3 column volumes of Ni-Buffer [20 mM Tris pH 8.0, 100 mM KCl, 5 mM imidazole, 
0.1% (w/v)  C10E6, 5% glycerol] and rocked for 3 h at + 4 °C. One milliliter of  Ni2+-NTA agarose resin binds 5 
to 10 mg of 8X-His fusion protein. The protein-resin slurry was poured into the chromatography column, and 
the flowthrough (FT) was collected slowly. The beads were washed sequentially with ten-bed volumes of pre-
chilled wash buffer I [20 mM Tris–HCl, pH 8.0, 500 mM KCl, 10 mM imidazole, 0.1% (w/v)  C10E6, 5% glycerol] 
and five-bed volumes of wash buffer II [20 mM Tris–HCl pH 8.0, 40 mM KCl, 20 mM imidazole, 0.1% (w/v) 
 C10E6, 5% glycerol]. Finally, the His-tagged hCOX-1 protein was eluted with 1–3 bed-volumes of elution buffer 
[20 mM Tris–HCl pH 8.0, 40 mM KCl, 250 mM Imidazole, 0.1% (w/v)  C10E6, 5% glycerol]. The FT fraction was 
subjected to a further chromatography step by re-incubating it with the resin in batch with gentle rotation, o/n. 
The hCOX-1 eluted fractions were combined and dialyzed o/n against 500 ml of no-imidazole buffer [20 mM 
Tris–HCl pH 8.0, 150 mM KCl, 0.1% (w/v)  C10E6, 5% glycerol]. Histidine tag was cleaved off with  TEV6His 
protease at 1∶40 (w/w) protease to protein ratio. After digestion, the reaction mixture was passed on fresh Ni-
beads to recapture the  protease16. hCOX-1 was recovered in the FT and beads were washed with buffer without 
imidazole [20 mM Tris–HCl pH 8.0, 100 mM KCl, 0.1% (w/v)  C10E6, 5% glycerol]. Protein purity was assessed 
by SDS-PAGE analysis followed by staining with Coomassie Brilliant Blue G-250. Protein concentration was 
assessed spectrophotometrically by NanoDrop 2000 (Thermo Scientific) measuring the absorbance at 280 nm 
using the theoretical molar extinction coefficient (96,720 M−1 cm−1) determined from the amino acid sequence 
and molecular weight to 70 kDa.
Cyclooxygenase activity evaluation by  O2 measurement‑based assay. Functional analysis of 
ovine and human COX-1 catalytic activity was determined by monitoring  O2 consumption by using an Oxy-
therm electrode unit (Hansatech), in the presence of arachidonic acid and different inhibitors. The instrument is 
equipped with a Clark-type oxygen electrode to monitor the dissolved oxygen concentration in a sealed meas-
urement chamber over the time. Oxygen consumption was measured at 37 °C directly in a 1000 µL reaction 
15
Vol.:(0123456789)
Scientific Reports |         (2021) 11:4312  | https://doi.org/10.1038/s41598-021-83438-z
www.nature.com/scientificreports/
vessel. Briefly, it follows the description of a typical assay: Oxygraph buffer (the opportune volume is adjusted 
to 1000 µL of final volume according to the volume of the protein), 5 µM hemin (1 µL), 100 µM arachidonic 
acid (20 µL) and inhibitor (10 µL) at the opportune concentrations. By this feasible approach, COX-inhibitory 
activity  (IC50) of known NSAIDs such as mofezolac, ibuprofen and indomethacin was evaluated. Mofezolac was 
chosen as an example of highly selective COX-1 inhibitor, while indomethacin and ibuprofen as non-selective 
COXs inhibitors.
Oxygen consumption determination (μmol/ml  O2) started after the addition of the ovine or human COX-1/
Sf9 sonicated pellet (C = 2.6 mg/ml) to the mixture containing Oxygraph buffer, arachidonic acid and test com-
pounds at the opportune concentrations. Assay mixture was allowed to equilibrate in the reaction vessel at 37 °C 
for several minutes until steady baseline was recorded. Uninfected Sf9 sonicated cells were used as a negative 
control. Stock solutions were prepared in a minimum volume of vehicle (DMSO).
Data were collected by a PC and analyzed by an Oxygraph Plus Software. The change in  O2 concentration, 
expressed as l micromole of oxygen per minute at 37 °C  (O2 consumed/min) were obtained from the first deriva-
tive of  [O2] versus time.
Protein crystallization, data collection, and structure determination. hCOX-1 was buffer 
exchanged against 20 mM HEPES at pH 7.3, 40 mM NaCl and 0.4% w/v β-octyl glucoside using an Amicon 
Ultra 4 ml concentrator (with membrane Ultracel-PL PLGC, MWCO 10 kDa) and concentrated to 15 mg/ml. 
As for COX-2, also COX-1 requires heme  (Fe3+–protoporphyrin IX) as a cofactor. Therefore, 1 mM protopor-
phyrin in DMSO was added to the protein solution in a 1:1 molar ratio. The solution was incubated at 4 °C for 
10 min and used for crystallization. Protein crystals were obtained in 2 weeks by using the sitting-drop vapor 
diffusion method at 293 °K by mixing 1.5 μL of protein solution with 1.5 μL of reservoir solution consisting of 
sodium citrate 0.7 and 0.58 M LiCl. The pH value of the reservoir solution was not adjusted. Crystallization 
experiments were performed at 10.4 mg/ml of protein concentration based on the previous optimization done 
using the Hampton Research Pre-Crystallization Test. Crystals were flash-frozen in liquid nitrogen after a quick 
dipping in a solution containing reservoir solution supplemented with 20% glycerol as cryoprotectant. X-ray dif-
fraction data collection was performed at the I04 beamline of Diamond Light Source Ltd Synchrotron (Didcot, 
Oxfordshire, UK) by using 0.9795 Å as wavelength. Data reduction was performed by  XIA235 in 3dii mode, thus 
using  XDS36 for indexing, scaling and merging.  TRUNCATE37 included in CCP4 crystallographic  suite38 was 
used to convert reflection intensities to amplitudes and to select reflections for  Rfree calculation. Data have been 
processed by  STARANISO39 to remove anisotropy. The REMO  program40 included in the package  SIR201441 was 
used to solve the structure by Molecular Replacement. Here, the crystallographic structure of ovine COX-1 (PDB 
code 5U6X)13, which has 92% of sequence identity with respect to the hCOX-1, was used as a starting model. 
Structural refinement was performed by using Phenix.refine42 included in the crystallographic suite  PHENIX43. 
Once refined, the hCOX-1 crystal structure has been validated using the PDB validation  server44 and deposited 
in the Protein DataBank with accession code 6Y3C. PISA  server20 was used to define hCOX-1 biological unit and 
PRO-ORIGAMI45 along with TOPDRAW 46 to determine and draw the protein topology.
Comparative structural analysis. The hCOX-1 crystal structure was compared with known COX-1 
from ovis aries (found by setting a search query in the PDB based on the sequence of oCOX-1 having Uni-
Prot code P05979, identity E-value = 106 and cutoff identity = 95%) and hCOX-2 structures (found by setting a 
search query in the PDB based on the sequence of hCOX-2 having UniProt code P35354, identity E-value = 106, 
and cutoff identity = 95%) by using residue-by-residue, Solvent Accessibility Surface Area (SASA) values, Carte-
sian coordinates of the Cα atoms and backbone dihedral angles. The first ones were calculated by the program 
 AREAIMOL47 included in the crystallographic suit CCP4, the second ones were used to calculate the root mean 
square deviation (RMSD) between pair of structures, though the program  SUPERPOSE48, the third ones were 
used to calculate the Protein Angular Value (PAV) associated to each  residue49. PAV is defined as:
where ψi and φi are the backbone dihedral angles of the i-th residue. PAV values range between 0° and 180° and 
represent the ψi + φi values expressed in degrees, avoiding the problem of range definition connected with the 
circular nature of the angular variables. PAV profiles of each structure were calculated through the script  TPAD50 
run on  VMD51 SASA, RMSD, and PAV profiles from different structures were separately analyzed by using Prin-
cipal Component Analysis (PCA) and hierarchic clustering implemented in the program  RootProf52. Crystal 
structures have been compared by considering individual chains of the biological unit. Solvent molecules, metal 
ions and ligands were removed from the PDB files, and protein residues between 34 and 583 were considered, 
as terminal residues were missing in some structural models. hCOX-2 and oCOX-1 sequences were aligned 
with the hCOX-1 one, so that to consider 550 residues regardless of the type of protein. PCA was performed 
by considering two chains for each crystal structure to ensure a uniform weighting. In the case of SASA, resi-
dues having missing side chain in the final model of at least one crystal structure are excluded from PCA. The 
coordinate errors of the structural models used for comparative analysis were estimated by the diffraction-data 
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where Natoms is the number of atoms in the model, Nobs is the number of independent reflections, C is the 
fractional data completeness, Rfree is the crystallographic R-factor and dmin is the data resolution. DPI has been 
calculated by using the program  SFCHECK54 when diffraction data are available, or by using Eq. (2) with infor-
mation given in the  PDB55–65.
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